SAN DIEGO– TriLink BioTechnologies, a Maravai LifeSciences company, has announced the launch of its first all-in-one mRNA synthesis kit featuring its proprietary CleanCap® capping technology. To mark the occasion, the company is donating kits to prominent academic institutions in the U.S. and Europe, reinforcing its commitment to advancing mRNA research and innovation.
The newly introduced in vitro transcription (IVT) kit is designed to streamline and enhance the mRNA synthesis process. According to TriLink, the kit can deliver up to twice the mRNA yield and reduce double-stranded RNA (dsRNA) by up to 85% compared to other kits currently available on the market. By integrating several high-performance components, the kit enables researchers to produce higher-quality mRNA more efficiently, with fewer handling steps and greater consistency.
Justin Barbosa, Vice President and General Manager of TriLink Discovery, emphasized the importance of simplifying research workflows. “This launch brings together a powerful suite of novel IVT components that reflect TriLink’s years of innovation in mRNA synthesis. With this single kit, researchers can generate more high-quality mRNA per reaction, optimizing both efficiency and performance.”
The kit includes CleanCap AG (3′ OMe) for co-transcriptional capping with over 95% capping efficiency, CleanScribe RNA Polymerase to reduce dsRNA formation, modified nucleotides like N1-methylpseudouridine for improved mRNA function, and CleanScript IVT for increased yield. It is currently the only commercially available IVT kit to include CleanCap AG (3′ OMe), a next-generation cap analog that enhances protein expression and simplifies the mRNA manufacturing process compared to older methods like ARCA or enzymatic capping.
To support cutting-edge research, TriLink is donating the first batch of kits to top academic institutions including the Center for RNA Therapeutics at Houston Methodist Research Institute, the Center of RNA Technologies and Therapeutics at UC San Diego, the University Medical Center Utrecht, the University of Oxford, and Yale School of Medicine. Each institution will receive ten kits, capable of producing up to 250 mg of capped mRNA in total.
Trey Martin, CEO of Maravai LifeSciences, said the donation symbolizes the company’s long-term commitment to mRNA science. “By supporting top research institutions, we’re investing in the next generation of mRNA innovators. These tools are critical for developing the therapies of tomorrow, and we’re proud to be contributing to that effort.”
TriLink, with over 25 years of experience in nucleic acid technology, is recognized as a global leader in the development and manufacturing of mRNA and oligonucleotide reagents. Its CleanCap technology has already been used in billions of doses of approved vaccines worldwide. With this launch, the company aims to further support both research and GMP-grade manufacturing in genomics and mRNA-based therapeutic development.
